(Q45928085)

English

Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients.

scientific article published in August 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19606452

Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19606452

0 references

Wakako Umene-Nakano

2

object named as

Wakako Umene-Nakano

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19606452

Reiji Yoshimura

1

object named as

Reiji Yoshimura

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19606452

9

object named as

Jun Nakamura

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19606452

Atsuko Ikenouchi-Sugita

6

object named as

Atsuko Ikenouchi-Sugita

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19606452

4

object named as

Nobuhisa Ueda

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19606452

7

object named as

Hikaru Hori

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19606452

3

object named as

Akihito Suzuki

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19606452

author name string

Kyoko Miyamoto

5

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19606452

Koichi Otani

8

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19606452

publication date

1 August 2009

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19606452

Human Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19606452

24

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19606452

6

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19606452

489-494

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19606452

Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Paroxetine serum concentrations in depressed patients and response to treatment

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Allelic Variation of Human Serotonin Transporter Gene Expression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Serotonin transporter gene polymorphism and antidepressant response

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Long term efficacy of paroxetine in major depression: A study with plasma levels

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of acute paroxetine treatment on the consumption of cigarette smoking and caffeine in depressed patients

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Paroxetine in major depression: correlating plasma concentrations and clinical response

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Effectiveness and tolerability of paroxetine controlled release (CR) in the treatment of major depressive disorder: an open-label, prospective, multi-center trial in Korea

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Saliva level of free 3-methoxy-4-hydroxyphenylglycol (MHPG) as a biological index of anxiety disorders.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical response to antidepressant treatment and 3-methoxy-4-hydroxyphenylglycol levels: mini review

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1043

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HUP.1043

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19606452

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19606452

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45928085&oldid=1741927037"